Few Early Alzheimer’s Patients Qualify for Lecanemab
Few people with early Alzheimer’s disease met eligibility criteria for the new anti-amyloid monoclonal antibody treatments lecanemab (Leqembi) and aducanumab (Aduhelm), cross-sectional data from the Mayo Clinic Study of Aging showed. Of 237 people with mild cognitive impairment or mild dementia and increased brain amyloid on PET, clinical trial inclusion and exclusion criteria narrowed the […]
Second Trial Participant Dies in Alzheimer’s Drug Study
Days before the release of promising phase III trial data of lecanemab, an investigational anti-amyloid drug for early Alzheimer’s disease, a death possibly linked to the treatment was reported. An unpublished case report featured in Science suggested the death of a 65-year-old lecanemab trial participant who also had cerebral amyloid angiopathy — a condition in […]